

## HIV-1 p17, p24

### Human Immunodeficiency Virus 1 Antigens recombinant, *E. coli*

Cat. No.	Amount
PR-1207	100 µg

For *in vitro* use only  
Quality guaranteed for 12 months  
Store at -20°C

#### Avoid freeze / thaw cycles

#### Form

Liquid. Supplied in PBS pH 7.8, NaCl, DTT and urea.

#### Application

May be used in ELISA and Western blots, excellent antigen for early detection of HIV seroconvertors with minimal specificity problems.

#### Specificity

Immuno reactive with all sera of HIV-1 infected individuals.

#### Purity

>95% by SDS-PAGE and RP-HPLC

#### Description

The protein contains the full-length sequence of HIV-1 core proteins: Core protein p17 (matrix protein), and Core protein p24 (major capsid protein).

The fusion protein was purified by proprietary chromatographic technique.

#### Background

HIV belongs to the retrovirus family, distinguished by possession of a viral reverse transcriptase that transcribes viral RNA into DNA which is integrated into the host-cell genome.

The outer envelope is acquired during virion budding and is studded with spikes formed by the two major viral-envelope glycoproteins (the surface protein gp120 and the transmembrane protein gp41).

The central core contains four viral proteins (p24 - the major capsid protein, p17 - a matrix protein, p9, and p7), two copies of the HIV RNA genome (to which p7 and p9 are bound), and three viral enzymes (reverse transcriptase, integrase, and protease) essential for viral replication.

#### Selected References:

- Wu *et al.* (2004) Total chemical synthesis of N-myristoylated HIV-1 matrix protein p17: structural and mechanistic implications of p17 myristoylation. *Proc. Natl. Acad. Sci. USA* **101**:11587.
- Ribas *et al.* (2003) Performance of a quantitative human immunodeficiency virus type 1 p24 antigen assay on various HIV-1 subtypes for the follow-up of human immunodeficiency type 1 seropositive individuals. *J. Virol. Methods* **113**:29.
- Schupbach *et al.* (2003) HIV-1 p24 antigen is a significant inverse correlate of CD4 T-cell change in patients with suppressed viremia under long-term antiretroviral therapy. *J. Acquir. Immune. Defic. Syndr.* **33**:292.